labetalol   Click here for help

GtoPdb Ligand ID: 7207

Synonyms: AH-5158A | Normodyne® | SCH-15719W | Trandate®
Approved drug
labetalol is an approved drug (FDA (1984))
Compound class: Synthetic organic
Comment: Marketed formulations may contain labetalol hydrochloride (PubChem CID 71412).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 5
Rotatable bonds 8
Topological polar surface area 96.57
Molecular weight 328.18
XLogP 3.66
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(CCc1ccccc1)NCC(c1ccc(c(c1)C(=N)O)O)O
Isomeric SMILES CC(CCc1ccccc1)NCC(c1ccc(c(c1)C(=N)O)O)O
InChI InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
InChI Key SGUAFYQXFOLMHL-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
3. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
PLoS ONE, 5 (11): e15487. [PMID:21152092]
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
5. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341]
6. Baker JG, Hall IP, Hill SJ. (2003)
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666]
7. Baker JG, Hall IP, Hill SJ. (2004)
Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production.
Mol Pharmacol, 65 (4): 986-98. [PMID:15044629]
8. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011)
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
FASEB J, 25 (12): 4486-97. [PMID:21865315]
9. Proudman RGW, Baker JG. (2021)
The selectivity of α-adrenoceptor agonists for the human α1A, α1B, and α1D-adrenoceptors.
Pharmacol Res Perspect, 9 (4): e00799. [PMID:34355529]
10. Proudman RGW, Pupo AS, Baker JG. (2020)
The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors.
Pharmacol Res Perspect, 8 (4): e00602. [PMID:32608144]